Avalo Therapeutics Files 2025 Proxy Statement
Ticker: AVTX · Form: DEF 14A · Filed: May 1, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | DEF 14A |
| Filed Date | May 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: AVTX
TL;DR
AVTX proxy filing out - exec pay details for 2024 released.
AI Summary
Avalo Therapeutics, Inc. (AVTX) filed a DEF 14A on May 1, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and corporate governance matters. Key individuals mentioned in relation to compensation for the 2024 fiscal year include Garry Neil, M.D., and Michael Cola.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance, enabling informed voting decisions at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing (DEF 14A) detailing executive compensation and corporate governance, not a filing that typically introduces new financial risks.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Filer of the DEF 14A
- Garry Neil, M.D. (person) — Executive compensation recipient for 2024
- Michael Cola (person) — Executive compensation recipient for 2024
- Cerecor Inc. (company) — Former company name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding executive compensation, director nominations, and other corporate governance matters ahead of the annual meeting.
For which fiscal year are the executive compensation details primarily being reported?
The executive compensation details are primarily being reported for the fiscal year ending December 31, 2024.
Who are the key individuals mentioned in relation to executive compensation for the 2024 fiscal year?
Garry Neil, M.D., and Michael Cola are mentioned in relation to executive compensation for the 2024 fiscal year.
What was Avalo Therapeutics' former company name?
Avalo Therapeutics' former company name was Cerecor Inc.
When was the company name changed from Cerecor Inc. to Avalo Therapeutics, Inc.?
The date of the name change from Cerecor Inc. was November 2, 2011.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 1, 2025 by Garry Neil, M.D. regarding Avalo Therapeutics, Inc. (AVTX).